Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

被引:7
作者
Rosen, Jeffrey B. [1 ]
Ballantyne, Christie M. [2 ,3 ]
Hsueh, Willa A. [4 ]
Lin, Jianxin [5 ]
Shah, Arvind K. [5 ]
Lowe, Robert S. [5 ]
Tershakovec, Andrew M. [5 ]
机构
[1] Clin Res South Florida, Coral Gables, FL 33134 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA
[4] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
来源
LIPIDS IN HEALTH AND DISEASE | 2015年 / 14卷
关键词
TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR RISK; HYPERCHOLESTEROLEMIA; EZETIMIBE; DYSLIPIDEMIA; COMBINATION; MANAGEMENT; SIMVASTATIN; PREVENTION; SUBCLASSES;
D O I
10.1186/s12944-015-0075-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug therapy. This study evaluated the effects of MetS factors (abdominal obesity, depleted high-density lipoprotein cholesterol [HDL-C], and elevated triglycerides, blood pressure, and fasting glucose) and IR on ezetimibe/simvastatin and atorvastatin treatment efficacy in patients with MetS. Methods: This post-hoc analysis of a multicenter, 6-week, double-blind, randomized, parallel group study of 1128 subjects with hypercholesterolemia, MetS, and moderately high/high CHD risk evaluated the effects of baseline MetS factors/IR on percent change from baseline in lipids, apolipoproteins, and high-sensitivity C-reactive protein (hs-CRP), after treatment with the usual starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin (10 mg, 20 mg) and next higher doses (10/40 mg versus 40 mg). Results: Ezetimibe/simvastatin and atorvastatin efficacy was generally consistent across MetS factor/IR subgroups. Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Triglycerides, very-LDL-C, and hs-CRP results were more variable but similar between treatment groups. Conclusion: The magnitude of lipid-altering effects produced by each treatment regimen was generally similar across all MetS and IR subgroups. Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles
    Winkler, K.
    Schewe, T.
    Puetz, G.
    Oeduenc, N.
    Schaefer, G.
    Siegel, E.
    Geisen, U.
    Abletshauser, C.
    Hoffmann, M. M.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (06) : 463 - 470
  • [42] Relationship between the metabolic syndrome and the insulin resistance in adults with type 2 diabetes risk
    Ignacio Coniglio, Raul
    Ferraris, Roberto
    Prieto, Andrea
    Alberto Vasquez, Luis
    Garro, Sandra
    Antonio Tripodi, Marco
    Maria Salgueiro, Ana
    Carlos Otero, Juan
    Marcela Malaspina, Maria
    Montiel, Hugo
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2013, 47 (01): : 25 - 35
  • [43] Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome
    O'Neill, Blair J.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (05) : 301 - 307
  • [44] Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome
    Bener, Abdulbari
    Dogan, Muzeyyen
    Barakat, Lolwa
    Al-Hamaq, Abdulla O. A. A.
    JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2014, 5 (03) : 180 - 187
  • [45] Metabolic risk factors in first acute coronary syndrome (MERIFACS) Study
    Rao, B. Hygriv
    Raju, N. S. Rama
    Raju, C. S. Srinivasa
    Patel, Pushpraj
    Korabathina, Radhika
    Raj, Jeffrey Pradeep
    Azam, Mohammed Sadiq
    Rao, B. Annaji
    Shivakumar, Yerra
    Abdullakutty, Jabir
    Raju, P. Krishnam
    INDIAN HEART JOURNAL, 2022, 74 (04) : 275 - 281
  • [46] PREVALENCE AND PREDICTORS OF METABOLIC SYNDROME IN PATIENTS WITH CORONARY ARTERY DISEASE
    Khan, Asif
    Saif, Mohsin
    Naqvi, Syeda Nargis Fatima
    Samad, Mohd Abdul
    Rasheed, S. Zahed
    Ishaq, Mohammad
    PAKISTAN HEART JOURNAL, 2018, 51 (04): : 280 - 285
  • [47] Evaluation of the Japanese Metabolic Syndrome Risk Score (JAMRISC): a newly developed questionnaire used as a screening tool for diagnosing metabolic syndrome and insulin resistance in Japan
    Tan, Ce
    Sasagawa, Yutaka
    Kamo, Ken-ichi
    Kukitsu, Takehiro
    Noda, Sayaka
    Ishikawa, Kazuma
    Yamauchi, Natsumi
    Saikawa, Takashi
    Noro, Takanori
    Nakamura, Hajime
    Takahashi, Fumihiko
    Sata, Fumihiro
    Tada, Mitsuhiro
    Kokai, Yasuo
    ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE, 2016, 21 (06) : 470 - 479
  • [48] Metabolic syndrome and chronic kidney disease as risk factors of osteoporosis
    Shin, Jung-ho
    Kim, Su Hyun
    Yu, Suk-Hee
    CLINICAL NEPHROLOGY, 2014, 81 (01) : 1 - 8
  • [49] Hypoglycemia: A Possible Link between Insulin Resistance, Metabolic Dyslipidemia, and Heart and Kidney Disease (the Cardiorenal Syndrome)
    Ensling, Myriam
    Steinmann, William
    Whaley-Connell, Adam
    CARDIORENAL MEDICINE, 2011, 1 (01) : 67 - 74
  • [50] Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category
    Polis, Adam B.
    Abate, Nicola
    Catapano, Alberico L.
    Ballantyne, Christie M.
    Davidson, Michael H.
    Smugar, Steven S.
    Tershakovec, Andrew M.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2009, 7 (06) : 601 - 610